Monoclonal Antibodies Market to 2017 - Multiple Indication Approvals and the Potential for MAbs in Oncology and Autoimmune Diseases are Re-Shaping the Market - GBI Research Reports

Monoclonal Antibodies Market to 2017 - Multiple Indication Approvals and the Potential for MAbs in Oncology and Autoimmune Diseases are Re-Shaping the Market

Monoclonal Antibodies Market to 2017 - Multiple Indication Approvals and the Potential for MAbs in Oncology and Autoimmune Diseases are Re-Shaping the Market - GBI Research Reports
Monoclonal Antibodies Market to 2017 - Multiple Indication Approvals and the Potential for MAbs in Oncology and Autoimmune Diseases are Re-Shaping the Market
Published Dec 01, 2011
172 pages — Published Dec 01, 2011
Price US$ 3,500.00  |  Buy this Report Now

About This Report

  
Abstract:

Summary

GBI Research, the leading business intelligence provider, has released its latest research Monoclonal Antibodies Market to 2017 - Multiple Indication Approvals and the Potential for MAbs in Oncology and Autoimmune Diseases are Re-Shaping the Market which provides insights about monoclonal antibodies sales forecasts until 2017. Monoclonal antibodies markets in the key geographies of the US, Europe and the Rest of The World are also covered in the report. The report also includes details about monoclonal antibodies R&D pipelines and potential future blockbuster products. The report provides in-depth analysis of therapeutic indication, which includes HER2 Breast Cancer, Bone Metastases and Bone Loss Due to Cancer Therapy, Relapsing-remitting Multiple Sclerosis (RRMS), Metastatic Non-Small Cell Lung Cancer (NSCLC) and Rheumatoid Arthritis. Furthermore, it includes market forecasts for each of the covered therapeutic indications. The report also explores the competitive landscape with a competitive analysis of the top companies in the market.

GBI Research analysis estimated the global monoclonal antibodies market to be valued at $15.6 billion in 2010, with a compound annual growth rate (CAGR) of 36.7% between 2002 and 2010. The market is forecast to grow at a CAGR of 10.6% between 2010 and 2017 and to reach $31.7billion by 2017. In-depth analysis in the report is based on propriety databases, primary and secondary research and inhouse analysis by the GBI Research team of experts.

GBI Research analysis found the R&D pipeline for the monoclonal antibodies market to be moderate. Many of the major pharmaceutical companies such as Roche, Amgen, and Johnson & Johnson are expanding into this market. This indicates that monoclonal antibodies R&D activity will remain active for at least the next four to five years.

Scope

- Data and analysis of the monoclonal antibodies market in the leading geographies of the world: the US and Europe. The indications treated by different classes of MAbs discussed, which are covered in this report are in breast cancer, bone loss & metastasis, RRMS, NSCLC and rheumatoid arthritis.
- Annualized market data for the monoclonal antibodies market from 2002 to 2010, with forecasts to 2017.
- Market data on the geographical landscape and therapeutic landscape, including market sizes, market shares, annual costs of therapy and sales volumes
- Key drivers and restraints that have had significant impact on the market.
- Competitive landscape of the global monoclonal antibodies market including benchmarking of the top companies. The key companies analysed in this report are Hoffman La Roche, Amgen, Abbott, Johnson & Johnson, Novartis, Biogen Idec, Merck, Eli Lilly

Reasons to buy

- Build effective strategies to launch pipeline products, by identifying potential geographies.
- Exploit in-licensing and out-licensing opportunities by identifying products to fill their portfolio gaps.
- Develop key strategic initiatives by studying the key strategies of the top competitors.
- Develop market-entry and market expansion strategies by identifying the geographic markets poised for strong growth.
- Reinforce R&D pipelines by identifying new target mechanisms which can produce first in class molecules with more efficiency and better safety.

  
Source:
Document ID
GBIHC152MR
Industry
Format:
PDF Adobe Acrobat
Buy Now

Sections

TitleStarting PageNumber of Pages
Table of Contents312
  List of Tables84
  List of Figures123
Monoclonal Antibodies Market to 2017 - Introduction152
  GBI Research Report Guidance161
Monoclonal Antibodies Market to 2017 - Market Characterization1720
  Introduction171
    Stability in the Body171
    Systemic Cancer Treatment171
    Targeted Therapy171
  Monoclonal Antibody Technology181
    Hybridoma Technology181
    FuCell Technology181
  Revenue Forecasts Global191
    Prescription Population191
    Annual Cost of Therapy202
    Revenue221
  Revenue Forecasts Countrywise231
    US231
    Europe241
    Rest of the World (ROW)251
  Treatment Usage Patterns261
    The US262
    Europe281
    ROW291
  Annual Cost of Therapy301
    The US301
    Europe311
    ROW321
  Global MAbs Trends331
    Market Trends331
      Big Pharmaceutical Companies Venturing into MAbs Market331
    Technology Trends331
      State-of-the-art R&D Technologies Expanding the Applications of MAbs to New Therapeutic Indications331
      New Screening Technologies to Foster Monoclonal Antibody Development331
  Product Trends331
    Research and Development Focus Shifted Towards Humanized and Fully Human MAbs331
      Horizontal Indication Expansion of Existing MAbs331
  Global MAbs Market Drivers341
    Gradual Growth in the Uptake of MAbs Have Driven the Monoclonal Antibody Sales Growth341
    Improved Side-effect Profiles and Tolerance of MAbs Therapy341
    Lack of Effective Conventional Therapies Accelerates Utilization of MAbs341
    Expanded Indications Opens up New Potential Patient Groups341
    Lack of Generics Augmented the Sales Growth of MAbs351
  Global MAbs Market Restraints351
    High Cost of MAbs Hampering the Growth of Treatment Population351
    Adverse Effects Generation of Antibodies against MAbs in Patients Receiving Monoclonal Antibody Therapy351
    Industry Challenges Majority of MAbs Receive Approvals as Last Option Therapies351
  Unmet Needs361
    Reduction in High Cost of MAb Therapies is the Major Unmet Need and it is also Responsible for Low Utilization by Patients361
    MAbs Do Not Cure Diseases; They either Treat Signs and Symptoms or Decelerate Cell Proliferation361
Monoclonal Antibodies Market to 2017 - Breast Cancer (Adjuvant and Metastatic)3727
  Overview371
  Introduction371
    Epidemiology381
    Diagnosis381
    Treatment391
  Prescription Population401
    Global402
    The US421
    Europe431
    ROW441
  Annual Cost of Therapy451
    Global451
    The US461
    Europe471
    ROW481
  Market Size491
    The US502
    Europe521
    ROW531
  Marketed Products541
    Herceptin (trastuzumab)541
      Product Overview541
      Mechanism of Action541
      Indications and Usage541
      Dosage541
  Pipeline Analysis551
    Phase lll562
    Phase ll583
    Phase l611
    Preclinical/Discovery621
  Promising Molecules631
    Pertuzumab (2C4, trade name Omnitarg)631
      Product Description631
      Mechanism of Action631
      Clinical Trials631
    Ramucirumab (IMC-1121B)631
      Product Description631
      Mechanism of Action631
      Clinical Trials631
MAbs Market Size in Bone Metastases and Bone Loss Due to Cancer Therapy6416
  Introduction641
  Epidemiology651
  Diagnosis651
  Treatment651
  Prescription Population661
    Global661
    The US671
    Europe681
    ROW691
  Annual Cost of Therapy701
    Global701
    The US711
    Europe721
    ROW731
  Market Size741
    Global741
    The US751
    Europe761
    ROW771
  Marketed Products781
    Xgeva (denosumab)781
      Product Overview781
      Mechanism of Action781
      Dosage781
  Pipeline Analysis791
    NDA Filed791
    Phase ll791
    Phase l791
    Preclinical/Discovery791
MAbs Market Size in Relapsing-Remitting Multiple Sclerosis (RRMS)8018
  Introduction801
  Epidemiology801
  Diagnosis801
  Treatment811
  Prescription Population811
    Global812
    The US831
    Europe841
    ROW851
  Annual Cost of Therapy861
    Global861
    The US871
    Europe881
    ROW891
  Market Size901
    Global901
    The US911
    Europe921
    ROW931
  Marketed Products941
    Description941
    Mechanism of Action941
    Indications and Usage941
    Dosage941
  Pipeline Analysis951
    Phase lll951
    Phase ll951
    Phase l961
    Preclinical/Discovery961
  Promising Molecules961
    Campath (Alemtuzumab)961
      Product Description961
      Mechanism of Action961
      Clinical Trials971
    Ocrelizumab971
      Product Description971
      Mechanism of Action971
      Clinical Trials971
MAbs Market Size in Metastatic Non-Small Cell Lung Cancer (NSCLC)9824
  Introduction981
  Epidemiology981
  Diagnosis982
  Prescription Population1001
    Global1001
    The US1011
    Europe1021
    ROW1031
  Annual Cost of Therapy1041
    Global1041
    The US1051
    Europe1061
    ROW1071
  Market Size1081
    Global1081
    The US1091
    Europe1101
    ROW1111
  Marketed Products1121
    Avastin1121
      Description1121
      Mechanism of Action1121
      Indications and Usage1121
      Dosage1121
  Pipeline Analysis1121
    Phase III1131
    Phase II1145
    Phase I1191
  Promising Molecule1201
    Necitimumab1201
      Product Description1201
      Mechanism of Action1201
      Clinical Trials1201
    Ramucirumab1211
      Product Description1211
      Mechanism of Action1211
      Clinical Trials1211
Monoclonal Antibodies Market to 2017 - Rheumatoid Arthritis12221
  Introduction1221
  Epidemiology1221
  Diagnosis1221
  Treatment1231
  Prescription Population1241
    Global1241
    The US1251
    Europe1261
    ROW1271
  Annual Cost of Therapy1281
    Global1281
    The US1291
    Europe1301
    ROW1311
  Market Size1321
    Global1321
    The US1331
    Europe1341
    ROW1351
  Marketed Products1361
    Rituxan1361
      Description1361
      Mechanism of Action1361
    Remicade1361
      Description1361
      Dosage1361
    Humira1361
      Description1361
      Mechanism of Action1361
    Cimzia1361
      Description1361
      Mechanism of Action1361
      Dosage1371
    Simponi1371
      Description1371
      Mechanism of Action1371
    Actemra1371
      Product Description1371
      Mechanism of Action1371
      Dosage and Administration1371
  Pipeline Analysis1381
    Phase III1381
    Phase II1391
    Phase I1401
    Preclinical/ Discovery Phase1401
  Promising Molecule1411
    Ofatumumab (Arzerra)1411
      Product Description1411
      Mechanism of Action1411
      Clinical Trials1411
    SAR153191(REGN88)1411

Table Of Contents

GBI Research Reports—GBI Research covers worldwide markets and issues, supplies actionable data and forecasts and is driven by industry leaders' insights. GBI Research provides a broad spectrum of reports across the healthcare and energy industries and its online offering is easy to navigate - a comprehensive resource for business information needs.

About the Author


Cite this Report

  
MLA:
GBI Research Reports. "Monoclonal Antibodies Market to 2017 - Multiple Indication Approvals and the Potential for MAbs in Oncology and Autoimmune Diseases are Re-Shaping the Market" Dec 01, 2011. Alacra Store. Nov 16, 2026. <http://www.alacrastore.com/storecontent/GBI-Research-Reports/Monoclonal-Antibodies-Market-to-2017-Multiple-Indication-Approvals-and-the-Potential-for-MAbs-in-Oncology-and-Autoimmune-Diseases-are-Re-Shaping-the-Market-2115-306>
  
APA:
GBI Research Reports. (2011). Monoclonal Antibodies Market to 2017 - Multiple Indication Approvals and the Potential for MAbs in Oncology and Autoimmune Diseases are Re-Shaping the Market Dec 01, 2011. New York, NY: Alacra Store. Retrieved Nov 16, 2026 from <http://www.alacrastore.com/storecontent/GBI-Research-Reports/Monoclonal-Antibodies-Market-to-2017-Multiple-Indication-Approvals-and-the-Potential-for-MAbs-in-Oncology-and-Autoimmune-Diseases-are-Re-Shaping-the-Market-2115-306>
  
US$ 3,500.00
$  £  €
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Market Research from one place.